Neurogene Inc.
For the period ended Dec 31, 2025. Filed Mar 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 24, 2026
NGNE$26.00+2.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
Consolidated Statements of Cash Flows
(In Thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(90,351) | $(75,144) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 14,183 | 8,320 |
| Depreciation and amortization of property and equipment | 3,043 | 3,195 |
| Asset impairment | 120 | 91 |
| Non-cash operating lease expense | 800 | 741 |
| Amortization of finance lease right-of-use assets | 49 | 52 |
| Amortization and accretion of premiums/discounts on held-to-maturity investments | (4,536) | (2,419) |
| Change in contingent value rights liability | (743) | 522 |
| Gain on lease modification | (6) | — |
| Changes in assets and liabilities: | ||
| Prepaid expenses and other current assets | 952 | (327) |
| Other assets | (58) | (211) |
| Accounts payable | 627 | (77) |
| Accrued expenses and other liabilities | 1,665 | (2,773) |
| Operating lease liabilities | (2,918) | (2,573) |
| Net cash used in operating activities | (77,173) | (70,603) |
| Investing activities | ||
| Purchases of property and equipment | (1,183) | (808) |
| Purchases of held-to-maturity investments | (269,513) | (198,453) |
| Proceeds from maturities of held-to-maturity investments | 284,700 | 74,000 |
| Net cash provided by (used in) investing activities | 14,004 | (125,261) |
| Financing activities | ||
| Payment of deferred offering costs related to at-the-market sales agreement | (241) | — |
| Proceeds from sale of common stock in at-the-market sales agreement, net of offering costs | 30,380 | — |
| Offering costs in connection with pre-closing financing | — | (4,287) |
| Transaction costs related to reverse merger | — | (2,855) |
| Proceeds from the issuance of common stock upon exercise of options | 266 | 1,676 |
| Proceeds from private financing, net of offering costs paid | — | 189,589 |
| Principal payments on finance leases | (61) | (52) |
| Proceeds from the issuance of common stock under Employee Stock Purchase Plan | 84 | — |
| Net cash provided by financing activities | 30,428 | 184,071 |
| Net decrease in cash, cash equivalents and restricted cash | (32,741) | (11,793) |
| Cash, cash equivalents and restricted cash at beginning of period | 136,925 | 148,718 |
| Cash, cash equivalents and restricted cash at end of period | $104,184 | $136,925 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Additions to operating lease right of use assets from new operating lease liabilities | $— | $60 |
| Property and equipment included in accounts payable and accrued expenses | $76 | $726 |
| Additions to finance lease right of use assets from new finance lease liabilities | $— | $25 |
| Offering costs related to private offering, included in accounts payable and accrued expenses | $— | $90 |
| Supplemental cash flow information: | ||
| Cash paid for interest | $5 | $12 |
| Deferred offering costs reclassified to additional paid-in capital | $50 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.